Epigenetics: Rethinking of Drug Research and Development

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2019 Nov 20

PMID 31741399

Citations 1

Authors

Kenneth Lundstrom

Affiliations

Soon will be listed here.

Citing Articles

Comprehensive Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology.

Sacilotto N, Dessanti P, Lufino M, Ortega A, Rodriguez-Gimeno A, Salas J ACS Pharmacol Transl Sci. 2021; 4(6):1818-1834.

PMID: 34927013 PMC: 8669716. DOI: 10.1021/acsptsci.1c00223.

References

Lockwood L, Su S, Youssef N . The role of epigenetics in depression and suicide: A platform for gene-environment interactions. Psychiatry Res. 2015; 228(3):235-42. DOI: 10.1016/j.psychres.2015.05.071. View

Padalino G, Ferla S, Brancale A, Chalmers I, Hoffmann K . Combining bioinformatics, cheminformatics, functional genomics and whole organism approaches for identifying epigenetic drug targets in Schistosoma mansoni. Int J Parasitol Drugs Drug Resist. 2018; 8(3):559-570. PMC: 6288008. DOI: 10.1016/j.ijpddr.2018.10.005. View

Mann B, Johnson J, Cohen M, Justice R, Pazdur R . FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007; 12(10):1247-52. DOI: 10.1634/theoncologist.12-10-1247. View

Park H, Chung H, Lee J, Jang J, Kim Y, Kim S . Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia. Yonsei Med J. 2016; 58(1):35-42. PMC: 5122650. DOI: 10.3349/ymj.2017.58.1.35. View

Kaminskas E, Farrell A, Wang Y, Sridhara R, Pazdur R . FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005; 10(3):176-82. DOI: 10.1634/theoncologist.10-3-176. View

Poole R . Belinostat: first global approval. Drugs. 2014; 74(13):1543-54. DOI: 10.1007/s40265-014-0275-8. View

Su L, Mahabir S, Ellison G, McGuinn L, Reid B . Epigenetic Contributions to the Relationship between Cancer and Dietary Intake of Nutrients, Bioactive Food Components, and Environmental Toxicants. Front Genet. 2012; 2:91. PMC: 3266615. DOI: 10.3389/fgene.2011.00091. View

Dzobo K . Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment "jigsaw puzzle". OMICS. 2019; 23(2):70-85. DOI: 10.1089/omi.2018.0206. View

Adams D, Gonzalez-Duarte A, ORiordan W, Yang C, Ueda M, Kristen A . Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018; 379(1):11-21. DOI: 10.1056/NEJMoa1716153. View

10.

Ribich S, Harvey D, Copeland R . Drug Discovery and Chemical Biology of Cancer Epigenetics. Cell Chem Biol. 2017; 24(9):1120-1147. DOI: 10.1016/j.chembiol.2017.08.020. View

11.

Kantarjian H, Roboz G, Kropf P, Yee K, OConnell C, Tibes R . Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017; 18(10):1317-1326. PMC: 5925750. DOI: 10.1016/S1470-2045(17)30576-4. View

12.

Mohammad H, Barbash O, Creasy C . Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer. Nat Med. 2019; 25(3):403-418. DOI: 10.1038/s41591-019-0376-8. View

13.

Lundstrom K . Epigenetics, Nutrition, Disease and Drug Development. Curr Drug Discov Technol. 2018; 16(4):386-391. DOI: 10.2174/1570163815666180419154954. View

14.

Cazaly E, Saad J, Wang W, Heckman C, Ollikainen M, Tang J . Making Sense of the Epigenome Using Data Integration Approaches. Front Pharmacol. 2019; 10:126. PMC: 6390500. DOI: 10.3389/fphar.2019.00126. View

15.

Lascano S, Lopez M, Arimondo P . Natural Products and Chemical Biology Tools: Alternatives to Target Epigenetic Mechanisms in Cancers. Chem Rec. 2018; 18(12):1854-1876. DOI: 10.1002/tcr.201800133. View

16.

Marimani M, Ahmad A, Duse A . The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2018; 113:200-214. DOI: 10.1016/j.tube.2018.10.009. View

17.

Woods D, Sodre A, Villagra A, Sarnaik A, Sotomayor E, Weber J . HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res. 2015; 3(12):1375-85. PMC: 4674300. DOI: 10.1158/2326-6066.CIR-15-0077-T. View

18.

Lundstrom K . Micro-RNA in disease and gene therapy. Curr Drug Discov Technol. 2011; 8(2):76-86. DOI: 10.2174/157016311795563857. View

19.

Manchia M, Fanos V . Targeting aggression in severe mental illness: The predictive role of genetic, epigenetic, and metabolomic markers. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 77:32-41. DOI: 10.1016/j.pnpbp.2017.03.024. View

20.

Oki Y, Buglio D, Fanale M, Fayad L, Copeland A, Romaguera J . Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res. 2013; 19(24):6882-90. PMC: 4409814. DOI: 10.1158/1078-0432.CCR-13-1906. View